Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer

Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori, Wainer Zoli

Research output: Contribution to journalArticle

Abstract

Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2%) (P =.037) were observed for ERCC1 expression (90%), and high predictivity of resistance (100%) but very low predictivity of sensitivity (40%) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5% sensitivity and 89% resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.

Original languageEnglish
Pages (from-to)122-127
Number of pages6
JournalClinical Colorectal Cancer
Volume12
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

oxaliplatin
Colonic Neoplasms
Biomarkers
Carcinoma
Fluorouracil
Gene Expression
Therapeutics
Drug Resistance
Pharmaceutical Preparations
Reverse Transcription
Decision Making
Biopsy
Polymerase Chain Reaction
In Vitro Techniques

Keywords

  • Colon cancer
  • ERCC1
  • In vitro chemosensitivity test
  • Peritoneal carcinomatosis
  • Response prediction
  • TS

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. / Arienti, Chiara; Tesei, Anna; Verdecchia, Giorgio Maria; Framarini, Massimo; Virzì, Salvatore; Grassi, Antonio; Scarpi, Emanuela; Turci, Livia; Silvestrini, Rosella; Amadori, Dino; Zoli, Wainer.

In: Clinical Colorectal Cancer, Vol. 12, No. 2, 2013, p. 122-127.

Research output: Contribution to journalArticle

Arienti, Chiara ; Tesei, Anna ; Verdecchia, Giorgio Maria ; Framarini, Massimo ; Virzì, Salvatore ; Grassi, Antonio ; Scarpi, Emanuela ; Turci, Livia ; Silvestrini, Rosella ; Amadori, Dino ; Zoli, Wainer. / Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. In: Clinical Colorectal Cancer. 2013 ; Vol. 12, No. 2. pp. 122-127.
@article{7b0fae327d5742e991bab0ab55648afe,
title = "Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer",
abstract = "Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2{\%}) (P =.037) were observed for ERCC1 expression (90{\%}), and high predictivity of resistance (100{\%}) but very low predictivity of sensitivity (40{\%}) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5{\%} sensitivity and 89{\%} resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.",
keywords = "Colon cancer, ERCC1, In vitro chemosensitivity test, Peritoneal carcinomatosis, Response prediction, TS",
author = "Chiara Arienti and Anna Tesei and Verdecchia, {Giorgio Maria} and Massimo Framarini and Salvatore Virz{\`i} and Antonio Grassi and Emanuela Scarpi and Livia Turci and Rosella Silvestrini and Dino Amadori and Wainer Zoli",
year = "2013",
doi = "10.1016/j.clcc.2012.11.006",
language = "English",
volume = "12",
pages = "122--127",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer

AU - Arienti, Chiara

AU - Tesei, Anna

AU - Verdecchia, Giorgio Maria

AU - Framarini, Massimo

AU - Virzì, Salvatore

AU - Grassi, Antonio

AU - Scarpi, Emanuela

AU - Turci, Livia

AU - Silvestrini, Rosella

AU - Amadori, Dino

AU - Zoli, Wainer

PY - 2013

Y1 - 2013

N2 - Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2%) (P =.037) were observed for ERCC1 expression (90%), and high predictivity of resistance (100%) but very low predictivity of sensitivity (40%) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5% sensitivity and 89% resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.

AB - Background: 5-Fluorouracil- or oxaliplatin-based regimens are the treatments of choice in patients with PC from colon cancer. There are currently no useful preclinical evaluations to guide the decision-making process for tailored therapy. The aim of the present study was to compare the advantages and limits of a conventional in vitro chemosensitivity test with those of a panel of biomolecular markers in predicting clinical response to different drugs used to treat colon cancer-derived PC. Patients and Methods: Fresh surgical biopsy specimens were obtained from 28 patients with peritoneal carcinomatosis from colon cancer. TS, TP, DPD, MDR1, MRP-1, MGMT, BRCA1, ERCC1, GSTP1, and XPD gene expression levels were determined by real-time reverse transcription polymerase chain reaction. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient. Results: Expression levels of the genes analyzed were generally poorly related to each other. TS and ERCC1 expression was inversely related to response to 5-FU-and/or oxaliplatin-containing regimens. Significant predictivity in terms of sensitivity but poor predictivity of resistance (56.2%) (P =.037) were observed for ERCC1 expression (90%), and high predictivity of resistance (100%) but very low predictivity of sensitivity (40%) (P =.014) were registered for TS. The best overall and significant predictivity was observed for chemosensitivity test results (62.5% sensitivity and 89% resistance; P =.005). Conclusions: Sensitivity and resistance to drugs used in vivo was better defined by the chemosensitivity test than by biomarker expression.

KW - Colon cancer

KW - ERCC1

KW - In vitro chemosensitivity test

KW - Peritoneal carcinomatosis

KW - Response prediction

KW - TS

UR - http://www.scopus.com/inward/record.url?scp=84876842335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876842335&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2012.11.006

DO - 10.1016/j.clcc.2012.11.006

M3 - Article

C2 - 23332421

AN - SCOPUS:84876842335

VL - 12

SP - 122

EP - 127

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -